Professor Georgina Long AO, medical director at Melanoma Institute Australia (MIA) and chair of melanoma medical oncology and translational research at The University of Sydney, presented the results of the Phase III INTerpath-001 clinical trial at the ESMO (European Society for Medical Oncology) Congress 2026.
“These findings are a foundational shift in our approach to cancer: harnessing the immune system in a more personalized way to reduce the risk of melanoma recurrence or death. This has not been achieved before in the history of cancer drug development. It is the coming together of technology, our biological understanding of cancer and the immune system, and the courage to take this idea into the clinic,” said Long